Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASCO & EHA 2024 Multiple Myeloma Highlights
26 June 2024 | Virtual Meeting
Presentation summaries of key multiple myeloma abstracts from ASCO & EHA 2024 featuring panel discussions with leading experts
The Post-ASCO & EHA 2024 Multiple Myeloma Highlights was supported by Legend Biotech. Supporters have no influence over the production of content.
Latest evidence with bi-specific antibodies
Talquetamab for R/R multiple myeloma
Leo Rasche Würzburg University Hospital, Würzburg, Germany
CAMMA 2: Cevostamab in R/R MM patients (triple-class refractory & received BCMA-targeted ADC or CAR T-cell)
Shaji Kumar Mayo Clinic, Rochester, MN, United States
LINKER-MM1: Depth and durability of response with linvoseltamab for R/R MM
Suzanne Lentzsch Columbia University Medical Center, New York, NY, United States
BBV-383 efficacy, safety and RP2D in R/R MM
Katja Weisel University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Session 1 panel discussion
Advances for transplant-eligible patients
GMMG-HD7: ISA + len + bort + dex for transplant-eligible NDMM
Marc Raab Heidelberg Myeloma Center, Heidelberg, Germany
CASSIOPEIA: DARA + D-VTD then DARA maintenance in TE NDMM
Cyrille Hulin Hôpital Haut Lévêque, Pessac, France
Session 2 panel discussion
Advances for transplant-ineligible patients
IMROZ: ISA-VRD vs VRD for transplant-ineligible NDMM
Meletios Dimopoulos University of Athens School of Medicine, Athens, Greece
ISA + Rd + V vs ISA-Rd in NDMM TI
Xavier Leleu Poitiers University Hospital, Poitiers, France
Session 3 panel discussion
Updates in additional therapy classes
CA057-003: MEZI, TAZ, and DEX for RRMM
Rakesh Popat University College London Hospitals NHS Foundation Trust, London, United Kingdom
I2D: iberdomide, IXA, DEX for elderly pts with MM
Cyrille Touzeau University of Nantes, Nantes, France
DREAMM-7: BVd vs DVd for R/R MM
Maria Victoria Mateos University Hospital of Salamanca, Salamanca, Spain
KARMMA-2: IDE-CEL for HR-MM without 1L ASCT
Xavier Leleu Poitiers University Hospital, Poitiers, France
Session 4 panel discussion
Supported by:
Silver Supporters
